David Hung, Nuvation Bio CEO
August 5, 2024 03:35 PM EDT
R&D

Nu­va­tion paus­es BET in­hibitor plans af­ter check­ing out in­ter­im Phase 1 da­ta

Max Bayer

Pharma Reporter

Nu­va­tion Bio won’t take its can­cer drug NUV-868 in­to a Phase 2 tri­al for now, fol­low­ing a look at in­ter­im safe­ty and ef­fi­ca­cy da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times